Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Hereditary Sensory and Autonomic Neuropathies 1Ataxia Telangiectasia 1

Interventions

Everolimus 5Alpelisib 4berzosertib 3PX-866 3Letrozole 3Fulvestrant 3Cetuximab 3Topotecan 2NVP-BKM120 2tipifarnib 1sotorasib 1serabelisib 1ribociclib 1pembrolizumab 1parsaclisib 1palbociclib 1gedatolisib 1duvelisib 1ceralasertib 1capivasertib 1binimetinib 1Trimetazidine 1Paclitaxel 1Oxaliplatin 1Leuprolide 1Leucovorin 1Irinotecan 1Goserelin 1Fluorouracil 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hereditary Sensory and Autonomic Neuropathies × BAY 1895344 × Clear all
NCT04095273 2024-04-02

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

Bayer

Phase 1 Completed
56 enrolled

Ataxia Telangiectasia, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡